Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeted protein degradation: mechanisms, strategies and application
Lin Zhao, Jia Zhao, Kunhong Zhong, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 405

Showing 1-25 of 405 citing articles:

Molecular Glues: The Adhesive Connecting Targeted Protein Degradation to the Clinic
Janet M. Sasso, Rumiana Tenchov, Dasheng Wang, et al.
Biochemistry (2022) Vol. 62, Iss. 3, pp. 601-623
Open Access | Times Cited: 107
Targeted protein degradation: from mechanisms to clinic
Jonathan M. Tsai, Radosław P. Nowak, Benjamin L. Ebert, et al.
Nature Reviews Molecular Cell Biology (2024) Vol. 25, Iss. 9, pp. 740-757
Closed Access | Times Cited: 87
Proximity-Based Modalities for Biology and Medicine
Xingui Liu, Alessio Ciulli
ACS Central Science (2023) Vol. 9, Iss. 7, pp. 1269-1284
Open Access | Times Cited: 83
Lysosomes as coordinators of cellular catabolism, metabolic signalling and organ physiology
Carmine Settembre, Rushika M. Perera
Nature Reviews Molecular Cell Biology (2023) Vol. 25, Iss. 3, pp. 223-245
Closed Access | Times Cited: 80
Emerging degrader technologies engaging lysosomal pathways
Yu Ding, Dong Xing, Yiyan Fei, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 21, pp. 8832-8876
Open Access | Times Cited: 76
Bifunctional Compounds as Molecular Degraders for Integrin-Facilitated Targeted Protein Degradation
Jiwei Zheng, Wanyi He, Jing Li, et al.
Journal of the American Chemical Society (2022) Vol. 144, Iss. 48, pp. 21831-21836
Closed Access | Times Cited: 69
The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics
Linghui Qian, Xuefen Lin, Xue Gao, et al.
Chemical Reviews (2023) Vol. 123, Iss. 12, pp. 7782-7853
Closed Access | Times Cited: 65
Extracellular targeted protein degradation: an emerging modality for drug discovery
James A. Wells, Kaan Kumru
Nature Reviews Drug Discovery (2023) Vol. 23, Iss. 2, pp. 126-140
Closed Access | Times Cited: 64
Targeted protein degradation directly engaging lysosomes or proteasomes
Jiseong Kim, Insuk Byun, Do Young Kim, et al.
Chemical Society Reviews (2024) Vol. 53, Iss. 7, pp. 3253-3272
Open Access | Times Cited: 24
Characteristic roadmap of linker governs the rational design of PROTACs
Yawen Dong, Tingting Ma, Ting Xu, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 10, pp. 4266-4295
Open Access | Times Cited: 22
Brain clearance of protein aggregates: a close-up on astrocytes
Veronica Giusti, G Kaur, Elena Giusto, et al.
Molecular Neurodegeneration (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 19
SF3A2 promotes progression and cisplatin resistance in triple-negative breast cancer via alternative splicing of MKRN1
Ling Deng, Li Liao, Yin‐Ling Zhang, et al.
Science Advances (2024) Vol. 10, Iss. 14
Open Access | Times Cited: 19
Nano-PROTACs: state of the art and perspectives
Jie Zhong, Ruiqi Zhao, Yuji Wang, et al.
Nanoscale (2024) Vol. 16, Iss. 9, pp. 4378-4391
Closed Access | Times Cited: 18
Targeting the undruggables—the power of protein degraders
Chao Zhang, Yongbo Liu, Guangchen Li, et al.
Science Bulletin (2024) Vol. 69, Iss. 11, pp. 1776-1797
Open Access | Times Cited: 18
PROTACs: Current and Future Potential as a Precision Medicine Strategy to Combat Cancer
Kailee A. Rutherford, Kirk J. McManus
Molecular Cancer Therapeutics (2024) Vol. 23, Iss. 4, pp. 454-463
Open Access | Times Cited: 17
Expanding the horizons of targeted protein degradation: A non-small molecule perspective
Xiaowei Huang, Fengbo Wu, Jing Ye, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 6, pp. 2402-2427
Open Access | Times Cited: 16
De novo design of peptide binders to conformationally diverse targets with contrastive language modeling
Suhaas Bhat, Kalyan Palepu, Lauren Hong, et al.
Science Advances (2025) Vol. 11, Iss. 4
Closed Access | Times Cited: 5
Second-generation anti-amyloid monoclonal antibodies for Alzheimer’s disease: current landscape and future perspectives
Byeong‐Hyeon Kim, Sujin Kim, Yunkwon Nam, et al.
Translational Neurodegeneration (2025) Vol. 14, Iss. 1
Open Access | Times Cited: 4
BRD4-targeted photodegradation nanoplatform for light activatable melanoma therapy
Shiman Lu, Zhaoqing Shi, Chendi Ding, et al.
Biomaterials (2025) Vol. 317, pp. 123101-123101
Closed Access | Times Cited: 2
Targeting intracellular cancer proteins with tumor‐microenvironment‐responsive bispecific nanobody‐PROTACs for enhanced therapeutic efficacy
Changping Deng, Jiacheng Ma, Yuping Liu, et al.
MedComm (2025) Vol. 6, Iss. 2
Open Access | Times Cited: 2
Receptor-ligand interactions for optimized endocytosis in targeted therapies
Yejin Sung, Young‐Jin Choi, Eun Sun Kim, et al.
Journal of Controlled Release (2025) Vol. 380, pp. 524-538
Open Access | Times Cited: 2
A covalent peptide-based lysosome-targeting protein degradation platform for cancer immunotherapy
Youmei Xiao, Zhuoying He, Wanqiong Li, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 2
Targeting Tau Protein with Proximity Inducing Modulators: A New Frontier to Combat Tauopathies
Elisa Uliassi, María Laura Bolognesi, Andrea Milelli
ACS Pharmacology & Translational Science (2025) Vol. 8, Iss. 3, pp. 654-672
Closed Access | Times Cited: 2
Development of a novel PROTAC using the nucleic acid aptamer as a targeting ligand for tumor selective degradation of nucleolin
Lin Zhang, Ling Li, Xia Wang, et al.
Molecular Therapy — Nucleic Acids (2022) Vol. 30, pp. 66-79
Open Access | Times Cited: 66
PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies
Nuwayo Ishimwe Sincere, Krishnan Anand, Sumel Ashique, et al.
Molecules (2023) Vol. 28, Iss. 10, pp. 4014-4014
Open Access | Times Cited: 37
Page 1 - Next Page

Scroll to top